Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 55 out of 100. Treatments

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Objectives To evaluate the efficacy of nizatidine, a histamine H2-blocking drug, in delaying the progression of cognitive impairment in older adults with Alzheimer disease (AD). Design A one-year, randomized, double-blind, placebo-controlled trial. Participants Fifty-one older men and women aged 67 to 96 years with AD were recruited from the Cache County Study on Memory in Aging. Methods Patients were stratified by age and by the presence of one or more epsilon 4 alleles at the APOE locus, then randomized to receive nizatidine 75 mg (Axid ARTM, Whitehall Robins) or a matching placebo tablet twice daily. Cognitive outcomes were assessed at baseline, six, and twelve months after enrollment using tests from the CERAD battery and additional measures of visuospatial memory, verbal memory, and verbal fluency. Results Subjects showed significant declines in language, fluency, and praxis but most measures of memory had already "bottomed out." Intention-to-treat and compliance-based analyses showed no effect of nizatidine on any of the cognitive outcome measures over the one-year study interval. Conclusions These results do not support claims for the efficacy of nizatidine in over-the-counter dosages as a means of preventing symptom progression in AD.

What this study adds

Evidence grade: High

This is a trial. In a one-year randomized trial of 51 older adults with Alzheimer disease, nizatidine had no effect on any cognitive outcome measure compared with placebo. The authors conclude these results do not support nizatidine as a way to prevent symptom progression.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Carlson, M. C., Tschanz, J. T., Norton, M. C., Welsh-Bohmer, K., Martin, B. K., & Breitner, J. C. (2002). H2 histamine receptor blockade in the treatment of Alzheimer disease: a randomized, double-blind, placebo-controlled trial of nizatidine. Alzheimer disease and associated disorders. https://doi.org/10.1097/00002093-200201000-00004

Vancouver

Carlson MC, Tschanz JT, Norton MC, Welsh-Bohmer K, Martin BK, Breitner JC. H2 histamine receptor blockade in the treatment of Alzheimer disease: a randomized, double-blind, placebo-controlled trial of nizatidine. Alzheimer disease and associated disorders. 2002. doi:10.1097/00002093-200201000-00004. PMID: 11882746.

BibTeX

@article{carlson2002-11882746,
  author  = {Carlson, M. C. and Tschanz, J. T. and Norton, M. C. and Welsh-Bohmer, K. and Martin, B. K. and Breitner, J. C.},
  title   = {{H2 histamine receptor blockade in the treatment of Alzheimer disease: a randomized, double-blind, placebo-controlled trial of nizatidine}},
  journal = {Alzheimer disease and associated disorders},
  year    = {2002},
  doi     = {10.1097/00002093-200201000-00004},
  pmid    = {11882746},
  url     = {https://doi.org/10.1097/00002093-200201000-00004}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

In a one-year randomized trial of 51 older adults with Alzheimer disease, nizatidine had no effect on any cognitive outcome measure compared with placebo. The authors conclude these results do not support nizatidine as a way to prevent symptom progression.

Study details

How this study scored 55/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 1 of 4; Study design 11 of 12; Strength of evidence 5 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 2 of 2; Times cited 3 of 7; Citations per year 0 of 5; Impact for its field and year 2 of 6; Cited by studies here 1 of 6; Still being cited 1 of 4; Senior author's track record 3 of 4; Institution's track record 2 of 3; Multicenter collaboration 1 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 55 of 100.55 of 100 points earned45 not earned

Published in a peer-reviewed journal, and it is a randomized controlled trial. Scored zero for sample size and effect reported because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Alzheimer disease and associated disorders)
Journal's citation record 1 / 4 Alzheimer Disease & Associated Disorders: journal h-index 131 (OpenAlex, 2026-10-29)
Study design 11 / 12 A randomized controlled trial (from PubMed type “Randomized Controlled Trial”)
Strength of evidence 5 / 5 Rated “high” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 2002 — older than 20 years, still counted
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (pubmed indexes it as a clinical or observational study)
Randomized / blinded 2 / 2 Randomized and blinded or placebo-controlled (as stated in the record)
Times cited 3 / 7 Cited 17 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.7 citations a year over 26 year(s) since 2002
Impact for its field and year 2 / 6 Cited 1.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 1 / 6 Cited by 1 other studies in this library
Still being cited 1 / 4 Cited 3 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author John C.S. Breitner: h-index 93 (OpenAlex, whole career)
Institution's track record 2 / 3 Johns Hopkins University: institution h-index 2,306 (OpenAlex)
Multicenter collaboration 1 / 3 OpenAlex lists 3 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 11882746)
Free to read 0 / 2 Behind a paywall — scores zero
Total 55 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

May need a subscription Unpaywall, Europe PMC and OpenAlex found no free copy of the full text (checked 10 Oct 2026), so the publisher may charge for it. The PubMed abstract is free.

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

1 study in the alzhub library lists this one in its references.

Related studies in Treatments from nearby years

Also tagged “trial”

783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Treatments

See all studies in Treatments →